BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee J, Sung PS, Yang H, Lee SK, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Bae SH, Choi JY, Yoon SK. A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC. J Clin Med 2020;9:E4121. [PMID: 33371271 DOI: 10.3390/jcm9124121] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Tan W, Zhang K, Chen X, Yang L, Zhu S, Wei Y, Xie Z, Chen Y, Shang C. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. Journal of Advanced Research 2022. [DOI: 10.1016/j.jare.2022.03.012] [Reference Citation Analysis]
2 Lee J, Han JW, Sung PS, Lee SK, Yang H, Nam HC, Yoo SH, Lee HL, Kim HY, Lee SW, Kwon JH, Jang JW, Kim CW, Nam SW, Oh JS, Chun HJ, Bae SH, Choi JY, Yoon SK. Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study. J Clin Med 2021;10:4045. [PMID: 34575160 DOI: 10.3390/jcm10184045] [Reference Citation Analysis]
3 Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC). Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open. [DOI: 10.1002/jgh3.12772] [Reference Citation Analysis]
4 Park DJ, Sung PS, Lee GW, Cho S, Kim SM, Kang BY, Hur W, Yang H, Lee SK, Lee SH, Jung ES, Seo CH, Ahn J, Choi HJ, You YK, Jang JW, Bae SH, Choi JY, Yoon SK. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma. Int J Mol Sci 2021;22:4710. [PMID: 33946835 DOI: 10.3390/ijms22094710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen R, Li L, Li Y, Song K, Shen C, Ma P, Wang Z. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study. J Gastrointest Oncol 2022;13:1367-75. [PMID: 35837188 DOI: 10.21037/jgo-22-525] [Reference Citation Analysis]
6 Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Manag Res 2021;13:9379-89. [PMID: 34992463 DOI: 10.2147/CMAR.S330195] [Reference Citation Analysis]
7 Sueshige Y, Shiraiwa K, Honda K, Tanaka R, Saito T, Tokoro M, Iwao M, Endo M, Arakawa M, Tatsuta R, Seike M, Murakami K, Itoh H. A Broad Range High-Throughput Assay for Lenvatinib Using Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry With Clinical Application in Patients With Hepatocellular Carcinoma. Ther Drug Monit 2021;43:664-71. [PMID: 34521802 DOI: 10.1097/FTD.0000000000000872] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Rapposelli IG, Tada T, Shimose S, Burgio V, Kumada T, Iwamoto H, Hiraoka A, Niizeki T, Atsukawa M, Koga H, Hirooka M, Torimura T, Iavarone M, Tortora R, Campani C, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Giuseppe Foschi F, Silletta M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Tanaka T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Rimini M, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver Int 2021;41:2997-3008. [PMID: 34250737 DOI: 10.1111/liv.15014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Luo J, Huang Z, Wang M, Li T, Huang J. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy. BMC Gastroenterol 2022;22:108. [PMID: 35260095 DOI: 10.1186/s12876-022-02129-9] [Reference Citation Analysis]